Originally published by our sister publication Pain Medicine News
The FDA has approved the next-generation SynchroMed III intrathecal drug delivery system (Medtronic) for patients with cancer pain, chronic pain, and severe spasticity.
SynchroMed III is a targeted drug delivery platform that alleviates symptoms by delivering medication directly to the fluid surrounding the spinal cord. SynchroMed III is an upgraded system compared to with the SynchroMed II system, featuring a new